Solange Peters
Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland · Centre hospitalier universitaire vaudois (CHUV) · Centre Hospitalier Universitaire Vaudois
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Solange Peters as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06284317 · A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.ETOP IBCSG Partners Foundation · recruiting · Non Small Cell Lung Cancer · study chair
- Ph3NCT04385368 · Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)AstraZeneca · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph2NCT03133546 · Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790METOP IBCSG Partners Foundation · completed · Non Small Cell Lung Cancer Metastatic · study chair
- Ph2NCT03134118 · Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)European Organisation for Research and Treatment of Cancer - EORTC · active not recruiting · Thymoma Type B3, Thymic Carcinoma · principal investigator
- Ph2NCT02434081 · NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung CarcinomaETOP IBCSG Partners Foundation · completed · Non-small Cell Lung Cancer Stage III · study chair
- Ph2NCT02369484 · Afatinib in NSCLC With HER2 MutationETOP IBCSG Partners Foundation · completed · NSCLC · study chair
- Ph3NCT02129699 · Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapyETOP IBCSG Partners Foundation · terminated · Lung Cancer Non-small Cell Stage IV · study chair
- Ph2NCT02046733 · Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseETOP IBCSG Partners Foundation · completed · Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer · study chair
- Ph3NCT01652469 · Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.ETOP IBCSG Partners Foundation · completed · Carcinoma, Non-Small-Cell Lung · study chair
- Ph2NCT01059188 · Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)Swiss Cancer Institute · completed · Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:26 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20192,327 citationsRCR 84.6
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 20172,061 citationsRCR 67.4
- 1,015 citationsRCR 56.5
- 713 citationsRCR 47.5
- 580 citationsRCR 23.5
- 557 citationsRCR 45.4
- 525 citationsRCR 19.2
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.J Clin Oncol · 2023410 citationsRCR 31.4
- 390 citationsRCR 14.0
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).J Clin Oncol · 2017335 citationsRCR 9.4